However, resistance continues to be a major obstacle, significantly limiting its efficacy in numerous patients.<h4>Objectives</h4>This review critically examines the challenges associated with CAR-T-cell therapy, with a particular focus on the role of apoptotic pathways in overcoming resistance.<h4>Methods</h4>We explore various strategies to sensitize tumor cells to CAR-T-cell-mediated apoptosis, including the use of combination therapies with BH3 mimetics, Mcl-1 inhibitors, IAP inhibitors, and HDAC inhibitors. Here, MCL1 is linked to neoplasm.